Product Details:
| Minimum Order Quantity | 10 Piece |
| Strength | 150iu |
| Formulation | Highly Purified (HP) |
| Dose Strength | 150 MG |
| Country of Origin | Made in India |
| BRAND | Puregraf 150 IU HP injection |
| Packaging Size | BOX |
| Packaging Type | Vial |
PUREGRAF 150 MG INJ contains HMG (Human Menopausal Gonadotropin) as its active ingredient. HMG is a medication that contains a combination of hormones, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are naturally produced by the pituitary gland in the brain. PUREGRAF 150 MG INJ is used in assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF) and other fertility treatments. It is typically prescribed to stimulate the development of multiple ovarian follicles in women undergoing fertility treatment. Here's how HMG works in fertility treatment: 1. Follicle-stimulating hormone (FSH) stimulates the growth and development of ovarian follicles, each of which contains an egg (oocyte). During a woman's menstrual cycle, one follicle typically becomes dominant and releases an egg during ovulation. However, in fertility treatment, multiple follicles are desired to increase the chances of successful fertilization and pregnancy. 2. Luteinizing hormone (LH) triggers ovulation, the release of a mature egg from the dominant follicle. In fertility treatment, the timing of ovulation is carefully controlled to optimize the chances of successful fertilization and implantation. PUREGRAF 150 MG INJ is administered by injection and is typically given subcutaneously (under the skin) or intramuscularly (into the muscle). The dosage and administration schedule may vary depending on individual patient factors and the specific fertility treatment protocol prescribed by a reproductive endocrinologist or fertility specialist. As with any fertility treatment, it's important to discuss the risks, benefits, and potential side effects of PUREGRAF 150 MG INJ with a healthcare provider before starting treatment. Common side effects may include injection site reactions, ovarian hyperstimulation syndrome (OHSS), and multiple gestation (twins or higher-order multiples). Close monitoring during treatment is essential to ensure safety and optimize treatment outcomes.
Additional Information:
- Production Capacity: 25000 injection per month
- Delivery Time: 2-5 Days
- Packaging Details: ALL MEDICINES ARE WELL PACKED IN BROWN CARD BOX WITH THARMACOLE AND PLASTIC TO MAKE DECENT PACKING AND PREVENT FROM ANY TYPE OF PRODUCT DAMAGE .
